<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00718718</url>
  </required_header>
  <id_info>
    <org_study_id>CR015214</org_study_id>
    <secondary_id>C1377T04</secondary_id>
    <secondary_id>2007-006603-20</secondary_id>
    <nct_id>NCT00718718</nct_id>
  </id_info>
  <brief_title>A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy</brief_title>
  <official_title>A Phase 2, 2-Part, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept, Dose-finding Study Evaluating the Efficacy and Safety of CNTO 136 Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centocor, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of subcutaneous (under
      the skin) administration of anti-interleukin-6 monoclonal antibody (CNTO 136) in reducing
      signs and symptoms of participants with active rheumatoid arthritis (RA) with methotrexate
      (MTX) therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, double-blind (neither physician nor participants knows the treatment
      that the participant receives), randomized (study medication is assigned by chance),
      placebo-controlled (an inactive substance is compared with a medication to test whether the
      medication has a real effect in a clinical study) study. This study will be conducted in 2
      parts (Part A and Part B). Each part consists of 3 phases: screening (approximately 1 month
      prior to the start of study medication), treatment phase (Part A: 22 weeks and Part B: 24
      weeks), and follow-up phase (approximately 4 months after the last administration of study
      medication). In Part A, participants will be randomly assigned to 2 groups to receive CNTO
      136 100 mg and placebo for 22 weeks. All participants in Part A, will be crossed over at Week
      12 from placebo to CNTO 136 (for Group 1) and from CNTO 136 to placebo (for Group 2). In Part
      B, participants will be randomly assigned to 5 groups to receive placebo and/or 1 of 3 doses
      of CNTO 136 (100mg, 50mg or 25mg) for 24 weeks. Participants in Part B, Group 1 will be
      crossed over at Week 12 from placebo to CNTO 136. All participants should be maintained on a
      stable dose of MTX for at least 6 weeks prior to the start of study medication through Week
      24. Safety will be evaluated by the assessment of adverse events, vital signs, clinical
      findings, 12-lead electrocardiogram, and clinical laboratory tests which will be monitored
      throughout the study. The total duration of study participation for a participant will be
      approximately 42 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 11, 2008</start_date>
  <completion_date type="Actual">March 3, 2011</completion_date>
  <primary_completion_date type="Actual">March 3, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 12 (Part B)</measure>
    <time_frame>Week 12</time_frame>
    <description>An American College of Rheumatology (ACR) 50 response is defined as greater than or equal to (&gt;=) 50 percent (%) improvement in both tender joint count (68 joints) and swollen joint count (66 joints) and &gt;= 50% improvement in 3 of the following 5 assessments: participant's assessment of pain using Visual Analogue Scale (Score) VAS (0-10 scale, 0=no pain and 10=worst possible pain), participant's global assessment of disease activity by using VAS (the scale ranges from 0 to 10, [0 = very well to 10 = very poor]), physician's global assessment of disease activity using VAS (the scale ranges from 0 to 10, [0=no arthritis activity to 10=extremely active arthritis]), participant's assessment of physical function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, the scale ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area), and serum C-reactive protein (CRP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Index Score 28 (DAS28) Based on C-reactive Protein (CRP) at Week 12 (Part A and Part B)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The DAS28 based on C-Reactive Protein (CRP) is a statistically derived index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. A negative change from baseline in DAS28 (CRP) (that is, a decrease from baseline) indicates improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 12 (Part A)</measure>
    <time_frame>Week 12</time_frame>
    <description>An ACR 50 response is defined as &gt;= 50% improvement in both tender joint count (68 joints) and swollen joint count (66 joints) and &gt;= 50% improvement in 3 of the following 5 assessments: Participant's assessment of pain using VAS (0-10 scale, 0=no pain and 10=worst possible pain), Participant's global assessment of disease activity by using VAS (the scale ranges from 0 to 10, [0 = very well to 10 = very poor]), Physician's global assessment of disease activity using VAS (the scale ranges from 0 to 10, [0=no arthritis activity to 10=extremely active arthritis]), Participant's assessment of physical function as measured by HAQ-DI (the scale ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area), and Serum CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Sirukumab Concentrations Through Week 38 (Part A)</measure>
    <time_frame>Week 0, Day 2, Day 5, Day 8, Day 11, Week 2, Week 4, Week 8, Week 10, Week 10 Day 4, Week 10 Day 7, Week 12, Week 14, Week 18, Week 22, Week 24, and Week 38</time_frame>
    <description>Sirukumab Concentrations in serum were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Sirukumab Concentrations Through Week 38 (Part B)</measure>
    <time_frame>Week 0, Day 5, Day 8, Day 11, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 24 Day4, Week 24 Day7, Week 26, Week 28, Week 30, Week 34 and Week 38</time_frame>
    <description>Sirukumab Concentrations in serum were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Improvement From Baseline in Serum C-Reactive Protein (CRP) At Week 2 (Part A and Part B)</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>Serum CRP is a marker of systemic inflammation. A negative change from baseline in CRP represents improvement.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">187</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Part A, Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo (Week 0 to Week 10) and later CNTO 136 100 mg (Week 12 to Week 22) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CNTO 136 100 mg (Week 0 to Week 10) and later placebo (Week 12 to Week 22) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo (Week 0 to Week 10) and later CNTO 136 100 mg (Week 12 to Week 24) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CNTO 136 100 mg (Week 0 to Week 24) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CNTO 136 100 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6, 10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CNTO 136 50 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6,10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CNTO 136 25 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6,10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNTO 136 100 mg</intervention_name>
    <description>CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.</description>
    <arm_group_label>Part A, Group 1</arm_group_label>
    <arm_group_label>Part A, Group 2</arm_group_label>
    <arm_group_label>Part B, Group 1</arm_group_label>
    <arm_group_label>Part B, Group 2</arm_group_label>
    <arm_group_label>Part B, Group 3</arm_group_label>
    <other_name>Sirukumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNTO 136 50 mg</intervention_name>
    <description>CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.</description>
    <arm_group_label>Part B, Group 4</arm_group_label>
    <other_name>Sirukumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNTO 136 25 mg</intervention_name>
    <description>CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.</description>
    <arm_group_label>Part B, Group 5</arm_group_label>
    <other_name>Sirukumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be adminstered subcutaneously as per the appropriate randomized arm.</description>
    <arm_group_label>Part A, Group 1</arm_group_label>
    <arm_group_label>Part A, Group 2</arm_group_label>
    <arm_group_label>Part B, Group 1</arm_group_label>
    <arm_group_label>Part B, Group 3</arm_group_label>
    <arm_group_label>Part B, Group 4</arm_group_label>
    <arm_group_label>Part B, Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Stable dose of methotrexate will be maintained through Week 24.</description>
    <arm_group_label>Part A, Group 1</arm_group_label>
    <arm_group_label>Part A, Group 2</arm_group_label>
    <arm_group_label>Part B, Group 1</arm_group_label>
    <arm_group_label>Part B, Group 2</arm_group_label>
    <arm_group_label>Part B, Group 3</arm_group_label>
    <arm_group_label>Part B, Group 4</arm_group_label>
    <arm_group_label>Part B, Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with rheumatoid arthritis (RA) for at least 4 months prior to screening

          -  Have been treated and having an inadequate response with the tolerated dose of
             methotrexate (MTX) (at least 15mg/week) for at least 4 months prior to screening. MTX
             doses of 10 or 12.5 mg/week are allowed if participant had intolerance of 15 mg/week

          -  MTX route of administration and dose (not to exceed 25 mg/week) should be stable for
             at least 6 weeks prior to the start of the study medication

          -  Have active RA as defined by persistent disease activity with at least 6 swollen and 6
             tender joints, at the time of screening and baseline, and either anti-cyclic
             citrullinated peptide antibody-positive or rheumatoid factor positive at screening

          -  C-reactive protein greater than or equal to 1.0 mg/dL (10 mg/L)

          -  Agree to use one of the contraception methods defined in the protocol

        Exclusion Criteria:

          -  Have inflammatory diseases other than RA that might confound the evaluation of the
             benefit of CNTO 136 therapy in arthritis

          -  Family history of/ have long QT syndrome; or a history of second or third-degree heart
             block

          -  Received systemic immunosuppressives or disease modifying antirheumatic drug other
             than MTX, sulfasalazine, hydroxychloroquine or chloroquine within 4 weeks prior to the
             start of study medication

          -  Received intra articular (into joints), intramuscular, or intravenous corticosteroids
             within 4 weeks prior to the start of study medication

          -  Positive human immunodeficiency virus test, hepatitis B or hepatitis C

          -  History of / have chronic or recurrent infectious disease, history of / active
             tuberculosis

          -  Have serious infection within 2 months prior to start of study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Centocor Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Centocor, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Győr</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kecskemét</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goshogawara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hitachi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawagoe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sasebo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomigusuku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dae-Gu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad De Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2008</study_first_submitted>
  <study_first_submitted_qc>July 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2008</study_first_posted>
  <results_first_submitted>October 22, 2017</results_first_submitted>
  <results_first_submitted_qc>October 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 4, 2017</results_first_posted>
  <disposition_first_submitted>September 15, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>September 15, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 21, 2011</disposition_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthritis, Rheumatoid</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Active Rheumatoid Arthritis</keyword>
  <keyword>CNTO 136</keyword>
  <keyword>Interleukin-6</keyword>
  <keyword>Anti-interleukin-6 monoclonal antibody</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Part A - Placebo (Wk 0-Wk 12)</title>
          <description>Participants received placebo subcutaneously (SC) at Week 0 and every 2 weeks (q2w) for 10 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Part A - Placebo Then Sirukumab (Wk 12 to End of Study)</title>
          <description>Participants received 100 mg of sirukumab subcutaneously at Weeks 0, 2 and every 2 weeks (q2w) for Week 10. Thereafter participants received placebo beginning at Weeks 12 and q2w through week 22.</description>
        </group>
        <group group_id="P3">
          <title>Part A - Sirukumab (Wk 0-Wk 12)</title>
          <description>Participants received 100 mg of sirukumab subcutaneously at Weeks 0, 2 and every 2 weeks (q2w) for Week 10.</description>
        </group>
        <group group_id="P4">
          <title>Part A - Sirukumab Then Placebo (Wk 12 to End of Study)</title>
          <description>Participants received placebo at Weeks 12 and q2w through Week 22.</description>
        </group>
        <group group_id="P5">
          <title>Part B - Placebo (Wk 0-Wk 12)</title>
          <description>Participants received placebo subcutaneously (SC) at Week 0 and q2w for 10 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Part B - Placebo Then Sirukumab 100 mg q2 Weeks</title>
          <description>Participants received placebo subcutaneously (SC) at Week 0 and every 2 weeks (q2w) for 10 weeks. Thereafter participants received sirukumab 100 mg beginning at Weeks 12 and q2w through week 24.</description>
        </group>
        <group group_id="P7">
          <title>Part B - Sirukumab 100mg q2w</title>
          <description>Participants received 100 mg of sirukumab subcutaneously at Weeks 0, 2 and every 2 weeks (q2w) through Week 24.</description>
        </group>
        <group group_id="P8">
          <title>Part B - Sirukumab 100mg q4w</title>
          <description>Participants received 100 mg of sirukumab subcutaneously every 4 weeks (q4w) for 24 weeks and in between placebo SC injections was received at Weeks 2, 6, and q4w through week 22.</description>
        </group>
        <group group_id="P9">
          <title>Part B - Sirukumab 50mg q4w</title>
          <description>Participants received 50 mg of sirukumab subcutaneously every 4 weeks (q4w) for 24 weeks and in between placebo SC injections was received at Weeks 2, 6, and q4w through week 22.</description>
        </group>
        <group group_id="P10">
          <title>Part B: Sirukumab 25 mg q4 Weeks</title>
          <description>Participants received 25 mg of sirukumabat subcutaneously at Week 0 and every 4 weeks (q4w) for 24 weeks and placebo SC injections at Weeks 2, 6, and q4w through week 22.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Prior to Week 12</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="30"/>
                <participants group_id="P8" count="30"/>
                <participants group_id="P9" count="30"/>
                <participants group_id="P10" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="29"/>
                <participants group_id="P8" count="28"/>
                <participants group_id="P9" count="28"/>
                <participants group_id="P10" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Week 12 to End of Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="27"/>
                <participants group_id="P7" count="29"/>
                <participants group_id="P8" count="28"/>
                <participants group_id="P9" count="28"/>
                <participants group_id="P10" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="26"/>
                <participants group_id="P7" count="29"/>
                <participants group_id="P8" count="28"/>
                <participants group_id="P9" count="28"/>
                <participants group_id="P10" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="24"/>
                <participants group_id="P7" count="27"/>
                <participants group_id="P8" count="27"/>
                <participants group_id="P9" count="27"/>
                <participants group_id="P10" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A: Placebo</title>
          <description>Participants received placebo subcutaneously (SC) at Week 0 and every 2 weeks (q2w) for 10 weeks. Thereafter participants received sirukumab 100 mg beginning at Weeks 12 and q2w through week 22.</description>
        </group>
        <group group_id="B2">
          <title>Part A: Sirukumab 100 mg q2 Weeks</title>
          <description>Participants received 100 mg of sirukumab subcutaneously at Weeks 0, 2 and every 2 weeks (q2w) for Week 10. Thereafter participants received placebo beginning at Week 12 and q2w through week 22.</description>
        </group>
        <group group_id="B3">
          <title>Part B: Placebo</title>
          <description>Participants received placebo subcutaneously (SC) at Week 0 and every 2 weeks (q2w) for 10 weeks. Thereafter participants received sirukumab 100 milligram (mg) beginning at Week 12 and q2w through week 24.</description>
        </group>
        <group group_id="B4">
          <title>Part B: Sirukumab 100 mg q2 Weeks</title>
          <description>Participants received 100 mg of sirukumab subcutaneously at Weeks 0, 2 and every 2 weeks (q2w) through Week 24.</description>
        </group>
        <group group_id="B5">
          <title>Part B: Sirukumab 100 mg q4 Weeks</title>
          <description>Participants received 100 mg of sirukumab subcutaneously at Week 0 and every 4 weeks (q4w) for 24 weeks and placebo SC injections at Weeks 2, 6, and q4w through week 22.</description>
        </group>
        <group group_id="B6">
          <title>Part B: Sirukumab 50 mg q4 Weeks</title>
          <description>Participants received 50 mg of sirukumab subcutaneously at Week 0 and every 4 weeks (q4w) for 24 weeks and placebo SC injections at Weeks 2, 6, and q4w through week 22.</description>
        </group>
        <group group_id="B7">
          <title>Part B: Sirukumab 25 mg q4 Weeks</title>
          <description>Participants received 25 mg of sirukumabat subcutaneously at Week 0 and every 4 weeks (q4w) for 24 weeks and placebo SC injections at Weeks 2, 6, and q4w through week 22.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="30"/>
            <count group_id="B6" value="30"/>
            <count group_id="B7" value="31"/>
            <count group_id="B8" value="187"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.2" spread="10.24"/>
                    <measurement group_id="B2" value="50.1" spread="10.72"/>
                    <measurement group_id="B3" value="54.1" spread="12.72"/>
                    <measurement group_id="B4" value="53.8" spread="13.02"/>
                    <measurement group_id="B5" value="52" spread="11"/>
                    <measurement group_id="B6" value="50.9" spread="10.29"/>
                    <measurement group_id="B7" value="52.8" spread="9.41"/>
                    <measurement group_id="B8" value="51.8" spread="11.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="153"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Republic of Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 12 (Part B)</title>
        <description>An American College of Rheumatology (ACR) 50 response is defined as greater than or equal to (&gt;=) 50 percent (%) improvement in both tender joint count (68 joints) and swollen joint count (66 joints) and &gt;= 50% improvement in 3 of the following 5 assessments: participant’s assessment of pain using Visual Analogue Scale (Score) VAS (0-10 scale, 0=no pain and 10=worst possible pain), participant’s global assessment of disease activity by using VAS (the scale ranges from 0 to 10, [0 = very well to 10 = very poor]), physician’s global assessment of disease activity using VAS (the scale ranges from 0 to 10, [0=no arthritis activity to 10=extremely active arthritis]), participant’s assessment of physical function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, the scale ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area), and serum C-reactive protein (CRP).</description>
        <time_frame>Week 12</time_frame>
        <population>Population analyzed included all randomized participants in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received placebo subcutaneously (SC) at Week 0 and every 2 weeks (q2w) for 10 weeks. Thereafter participants received sirukumab 100 milligram (mg) beginning at Week 12 and q2w through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Sirukumab 100 mg q2 Weeks</title>
            <description>Participants received 100 mg of sirukumab subcutaneously at Weeks 0, 2 and every 2 weeks (q2w) through Week 24.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Sirukumab 100 mg q4 Weeks</title>
            <description>Participants received 100 mg of sirukumab subcutaneously at Week 0 and every 4 weeks (q4w) for 24 weeks and placebo SC injections at Weeks 2, 6, and q4w through week 22.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Sirukumab 50 mg q4 Weeks</title>
            <description>Participants received 50 mg of sirukumab subcutaneously at Week 0 and every 4 weeks (q4w) for 24 weeks and placebo SC injections at Weeks 2, 6, and q4w through week 22.</description>
          </group>
          <group group_id="O5">
            <title>Part B: Sirukumab 25 mg q4 Weeks</title>
            <description>Participants received 25 mg of sirukumabat subcutaneously at Week 0 and every 4 weeks (q4w) for 24 weeks and placebo SC injections at Weeks 2, 6, and q4w through week 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 12 (Part B)</title>
          <description>An American College of Rheumatology (ACR) 50 response is defined as greater than or equal to (&gt;=) 50 percent (%) improvement in both tender joint count (68 joints) and swollen joint count (66 joints) and &gt;= 50% improvement in 3 of the following 5 assessments: participant’s assessment of pain using Visual Analogue Scale (Score) VAS (0-10 scale, 0=no pain and 10=worst possible pain), participant’s global assessment of disease activity by using VAS (the scale ranges from 0 to 10, [0 = very well to 10 = very poor]), physician’s global assessment of disease activity using VAS (the scale ranges from 0 to 10, [0=no arthritis activity to 10=extremely active arthritis]), participant’s assessment of physical function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, the scale ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area), and serum C-reactive protein (CRP).</description>
          <population>Population analyzed included all randomized participants in Part B.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="26.7"/>
                    <measurement group_id="O3" value="23.3"/>
                    <measurement group_id="O4" value="26.7"/>
                    <measurement group_id="O5" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.052</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.104</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Index Score 28 (DAS28) Based on C-reactive Protein (CRP) at Week 12 (Part A and Part B)</title>
        <description>The DAS28 based on C-Reactive Protein (CRP) is a statistically derived index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. A negative change from baseline in DAS28 (CRP) (that is, a decrease from baseline) indicates improvement from baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Population analyzed included randomized subjects in Part A (excluding a site based on sponsor audit for data integrity) and Part B. Here 'n' signifies participants who were evaluable at specific time points, for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received placebo subcutaneously (SC) at Week 0 and every 2 weeks (q2w) for 10 weeks. Thereafter participants received sirukumab 100 mg beginning at Weeks 12 and q2w through week 22.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Sirukumab 100 mg q2 Weeks</title>
            <description>Participants received 100 mg of sirukumab subcutaneously at Weeks 0, 2 and every 2 weeks (q2w) for Week 10. Thereafter participants received placebo beginning at Weeks 12 and q2w through week 22.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Placebo</title>
            <description>Participants received placebo subcutaneously (SC) at Week 0 and every 2 weeks (q2w) for 10 weeks. Thereafter participants received sirukumab 100 milligram (mg) beginning at Week 12 and q2w through week 24.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Sirukumab 100 mg q2 Weeks</title>
            <description>Participants received 100 mg of sirukumab subcutaneously at Weeks 0, 2 and every 2 weeks (q2w) through Week 24.</description>
          </group>
          <group group_id="O5">
            <title>Part B: Sirukumab 100 mg q4 Weeks</title>
            <description>Participants received 100 mg of sirukumab subcutaneously at Week 0 and every 4 weeks (q4w) for 24 weeks and placebo SC injections at Weeks 2, 6, and q4w through week 22.</description>
          </group>
          <group group_id="O6">
            <title>Part B: Sirukumab 50 mg q4 Weeks</title>
            <description>Participants received 50 mg of sirukumab subcutaneously at Week 0 and every 4 weeks (q4w) for 24 weeks and placebo SC injections at Weeks 2, 6, and q4w through week 22.</description>
          </group>
          <group group_id="O7">
            <title>Part B: Sirukumab 25 mg q4 Weeks</title>
            <description>Participants received 25 mg of sirukumabat subcutaneously at Week 0 and every 4 weeks (q4w) for 24 weeks and placebo SC injections at Weeks 2, 6, and q4w through week 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Index Score 28 (DAS28) Based on C-reactive Protein (CRP) at Week 12 (Part A and Part B)</title>
          <description>The DAS28 based on C-Reactive Protein (CRP) is a statistically derived index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. A negative change from baseline in DAS28 (CRP) (that is, a decrease from baseline) indicates improvement from baseline.</description>
          <population>Population analyzed included randomized subjects in Part A (excluding a site based on sponsor audit for data integrity) and Part B. Here 'n' signifies participants who were evaluable at specific time points, for each arm, respectively.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.341" spread="0.9034"/>
                    <measurement group_id="O2" value="5.919" spread="0.9676"/>
                    <measurement group_id="O3" value="5.908" spread="0.7332"/>
                    <measurement group_id="O4" value="5.755" spread="0.9706"/>
                    <measurement group_id="O5" value="6.190" spread="0.6829"/>
                    <measurement group_id="O6" value="6.051" spread="0.8791"/>
                    <measurement group_id="O7" value="5.688" spread="0.9529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.619" spread="0.8541"/>
                    <measurement group_id="O2" value="-2.075" spread="0.7979"/>
                    <measurement group_id="O3" value="-1.073" spread="0.9766"/>
                    <measurement group_id="O4" value="-2.248" spread="1.2050"/>
                    <measurement group_id="O5" value="-2.011" spread="0.8843"/>
                    <measurement group_id="O6" value="-2.198" spread="0.8550"/>
                    <measurement group_id="O7" value="-1.964" spread="0.9532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Van Der Waerden ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Van Der Waerden ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Van Der Waerden ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Van Der Waerden ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Van Der Waerden ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 12 (Part A)</title>
        <description>An ACR 50 response is defined as &gt;= 50% improvement in both tender joint count (68 joints) and swollen joint count (66 joints) and &gt;= 50% improvement in 3 of the following 5 assessments: Participant’s assessment of pain using VAS (0-10 scale, 0=no pain and 10=worst possible pain), Participant’s global assessment of disease activity by using VAS (the scale ranges from 0 to 10, [0 = very well to 10 = very poor]), Physician’s global assessment of disease activity using VAS (the scale ranges from 0 to 10, [0=no arthritis activity to 10=extremely active arthritis]), Participant’s assessment of physical function as measured by HAQ-DI (the scale ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area), and Serum CRP.</description>
        <time_frame>Week 12</time_frame>
        <population>Population analyzed included all randomized participants in Part A (excluding a site based on sponsor audit for data integrity). Here 'N'(number of participants analyzed) signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received placebo subcutaneously (SC) at Week 0 and every 2 weeks (q2w) for 10 weeks. Thereafter participants received sirukumab 100 mg beginning at Weeks 12 and q2w through week 22.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Sirukumab 100 mg q2 Weeks</title>
            <description>Participants received 100 mg of sirukumab subcutaneously at Weeks 0, 2 and every 2 weeks (q2w) for Week 10. Thereafter participants received placebo beginning at Weeks 12 and q2w through week 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 12 (Part A)</title>
          <description>An ACR 50 response is defined as &gt;= 50% improvement in both tender joint count (68 joints) and swollen joint count (66 joints) and &gt;= 50% improvement in 3 of the following 5 assessments: Participant’s assessment of pain using VAS (0-10 scale, 0=no pain and 10=worst possible pain), Participant’s global assessment of disease activity by using VAS (the scale ranges from 0 to 10, [0 = very well to 10 = very poor]), Physician’s global assessment of disease activity using VAS (the scale ranges from 0 to 10, [0=no arthritis activity to 10=extremely active arthritis]), Participant’s assessment of physical function as measured by HAQ-DI (the scale ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area), and Serum CRP.</description>
          <population>Population analyzed included all randomized participants in Part A (excluding a site based on sponsor audit for data integrity). Here 'N'(number of participants analyzed) signifies participants who were evaluable for this outcome measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.148</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Sirukumab Concentrations Through Week 38 (Part A)</title>
        <description>Sirukumab Concentrations in serum were measured.</description>
        <time_frame>Week 0, Day 2, Day 5, Day 8, Day 11, Week 2, Week 4, Week 8, Week 10, Week 10 Day 4, Week 10 Day 7, Week 12, Week 14, Week 18, Week 22, Week 24, and Week 38</time_frame>
        <population>Population analyzed included participants treated with CNTO 136 (Sirukumab) in Part A (excluding a site based on sponsor audit for data integrity). Here 'N' (number of participants analyzed) signifies participants evaluable for this outcome measure whereas 'n' signifies participants evaluable at specific time points, for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received placebo subcutaneously (SC) at Week 0 and every 2 weeks (q2w) for 10 weeks. Thereafter participants received sirukumab 100 mg beginning at Weeks 12 and q2w through week 22.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Sirukumab 100 mg q2 Weeks</title>
            <description>Participants received 100 mg of sirukumab subcutaneously at Weeks 0, 2 and every 2 weeks (q2w) for Week 10. Thereafter participants received placebo beginning at Weeks 12 and q2w through week 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Sirukumab Concentrations Through Week 38 (Part A)</title>
          <description>Sirukumab Concentrations in serum were measured.</description>
          <population>Population analyzed included participants treated with CNTO 136 (Sirukumab) in Part A (excluding a site based on sponsor audit for data integrity). Here 'N' (number of participants analyzed) signifies participants evaluable for this outcome measure whereas 'n' signifies participants evaluable at specific time points, for each arm, respectively.</population>
          <units>Microgram per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below lower limit of quantification (LLOQ) (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="0.01" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="3.73" spread="2.581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="7.40" spread="3.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="6.01" spread="2.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="5.42" spread="1.866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="4.78" spread="1.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="8.83" spread="3.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="10.49" spread="3.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="12.36" spread="3.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="13.49" spread="3.670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="19.07" spread="4.630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="18.71" spread="4.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="14.31" spread="3.438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" spread="1.779"/>
                    <measurement group_id="O2" value="7.07" spread="2.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.52" spread="4.338"/>
                    <measurement group_id="O2" value="2.74" spread="1.737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.79" spread="5.830"/>
                    <measurement group_id="O2" value="1.18" spread="0.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.37" spread="6.177"/>
                    <measurement group_id="O2" value="0.88" spread="0.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 38</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.525"/>
                    <measurement group_id="O2" value="0.02" spread="0.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Sirukumab Concentrations Through Week 38 (Part B)</title>
        <description>Sirukumab Concentrations in serum were measured.</description>
        <time_frame>Week 0, Day 5, Day 8, Day 11, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 24 Day4, Week 24 Day7, Week 26, Week 28, Week 30, Week 34 and Week 38</time_frame>
        <population>Population analyzed included participants treated with CNTO 136 (Sirukumab) in Part B. Here 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure whereas 'n' signifies participants who were evaluable at specific time points, for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received placebo subcutaneously (SC) at Week 0 and every 2 weeks (q2w) for 10 weeks. Thereafter participants received sirukumab 100 milligram (mg) beginning at Week 12 and q2w through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Sirukumab 100 mg q2 Weeks</title>
            <description>Participants received 100 mg of sirukumab subcutaneously at Weeks 0, 2 and every 2 weeks (q2w) through Week 24.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Sirukumab 100 mg q4 Weeks</title>
            <description>Participants received 100 mg of sirukumab subcutaneously at Week 0 and every 4 weeks (q4w) for 24 weeks and placebo SC injections at Weeks 2, 6, and q4w through week 22.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Sirukumab 50 mg q4 Weeks</title>
            <description>Participants received 50 mg of sirukumab subcutaneously at Week 0 and every 4 weeks (q4w) for 24 weeks and placebo SC injections at Weeks 2, 6, and q4w through week 22.</description>
          </group>
          <group group_id="O5">
            <title>Part B: Sirukumab 25 mg q4 Weeks</title>
            <description>Participants received 25 mg of sirukumabat subcutaneously at Week 0 and every 4 weeks (q4w) for 24 weeks and placebo SC injections at Weeks 2, 6, and q4w through week 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Sirukumab Concentrations Through Week 38 (Part B)</title>
          <description>Sirukumab Concentrations in serum were measured.</description>
          <population>Population analyzed included participants treated with CNTO 136 (Sirukumab) in Part B. Here 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure whereas 'n' signifies participants who were evaluable at specific time points, for each arm, respectively.</population>
          <units>Microgram per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="0.03" spread="0.087"/>
                    <measurement group_id="O3" value="0.00" spread="0.000"/>
                    <measurement group_id="O4" value="0.02" spread="0.076"/>
                    <measurement group_id="O5" value="0.01" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="6.75" spread="3.212"/>
                    <measurement group_id="O3" value="6.21" spread="2.933"/>
                    <measurement group_id="O4" value="2.66" spread="1.447"/>
                    <measurement group_id="O5" value="1.59" spread="0.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="5.67" spread="2.398"/>
                    <measurement group_id="O3" value="5.85" spread="2.774"/>
                    <measurement group_id="O4" value="2.61" spread="1.339"/>
                    <measurement group_id="O5" value="1.49" spread="0.556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.063"/>
                    <measurement group_id="O2" value="4.50" spread="2.307"/>
                    <measurement group_id="O3" value="4.68" spread="2.539"/>
                    <measurement group_id="O4" value="2.54" spread="1.233"/>
                    <measurement group_id="O5" value="1.26" spread="0.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="4.30" spread="2.265"/>
                    <measurement group_id="O3" value="3.81" spread="1.934"/>
                    <measurement group_id="O4" value="1.97" spread="0.916"/>
                    <measurement group_id="O5" value="1.16" spread="0.426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="7.16" spread="3.290"/>
                    <measurement group_id="O3" value="2.02" spread="1.073"/>
                    <measurement group_id="O4" value="0.97" spread="0.470"/>
                    <measurement group_id="O5" value="0.85" spread="1.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="10.54" spread="5.008"/>
                    <measurement group_id="O3" value="3.08" spread="1.806"/>
                    <measurement group_id="O4" value="1.45" spread="0.764"/>
                    <measurement group_id="O5" value="0.99" spread="0.560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as the values were below LLOQ (0.0977 microgram per milliliter).</measurement>
                    <measurement group_id="O2" value="11.63" spread="5.232"/>
                    <measurement group_id="O3" value="3.10" spread="1.633"/>
                    <measurement group_id="O4" value="1.79" spread="0.836"/>
                    <measurement group_id="O5" value="0.99" spread="0.478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.84" spread="2.270"/>
                    <measurement group_id="O2" value="9.96" spread="5.107"/>
                    <measurement group_id="O3" value="3.51" spread="2.545"/>
                    <measurement group_id="O4" value="2.03" spread="1.366"/>
                    <measurement group_id="O5" value="0.98" spread="0.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.94" spread="3.646"/>
                    <measurement group_id="O2" value="10.29" spread="4.951"/>
                    <measurement group_id="O3" value="3.92" spread="2.665"/>
                    <measurement group_id="O4" value="1.80" spread="1.030"/>
                    <measurement group_id="O5" value="1.03" spread="0.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.04" spread="4.607"/>
                    <measurement group_id="O2" value="10.73" spread="5.182"/>
                    <measurement group_id="O3" value="3.80" spread="2.815"/>
                    <measurement group_id="O4" value="1.89" spread="1.042"/>
                    <measurement group_id="O5" value="1.04" spread="0.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.46" spread="6.826"/>
                    <measurement group_id="O2" value="17.34" spread="9.046"/>
                    <measurement group_id="O3" value="9.06" spread="5.632"/>
                    <measurement group_id="O4" value="4.42" spread="1.293"/>
                    <measurement group_id="O5" value="3.36" spread="1.578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.14" spread="5.991"/>
                    <measurement group_id="O2" value="15.01" spread="7.853"/>
                    <measurement group_id="O3" value="9.58" spread="5.721"/>
                    <measurement group_id="O4" value="4.52" spread="1.719"/>
                    <measurement group_id="O5" value="2.80" spread="1.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.97" spread="4.565"/>
                    <measurement group_id="O2" value="10.09" spread="6.808"/>
                    <measurement group_id="O3" value="6.49" spread="5.401"/>
                    <measurement group_id="O4" value="3.72" spread="1.434"/>
                    <measurement group_id="O5" value="1.91" spread="1.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93" spread="3.378"/>
                    <measurement group_id="O2" value="6.69" spread="4.329"/>
                    <measurement group_id="O3" value="4.15" spread="2.830"/>
                    <measurement group_id="O4" value="1.84" spread="0.764"/>
                    <measurement group_id="O5" value="1.06" spread="0.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.49" spread="2.708"/>
                    <measurement group_id="O2" value="4.06" spread="2.341"/>
                    <measurement group_id="O3" value="2.42" spread="1.931"/>
                    <measurement group_id="O4" value="1.07" spread="0.529"/>
                    <measurement group_id="O5" value="0.52" spread="0.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="1.451"/>
                    <measurement group_id="O2" value="1.92" spread="1.403"/>
                    <measurement group_id="O3" value="0.94" spread="0.948"/>
                    <measurement group_id="O4" value="0.39" spread="0.396"/>
                    <measurement group_id="O5" value="0.10" spread="0.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 38</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.756"/>
                    <measurement group_id="O2" value="0.72" spread="0.704"/>
                    <measurement group_id="O3" value="0.29" spread="0.382"/>
                    <measurement group_id="O4" value="0.08" spread="0.114"/>
                    <measurement group_id="O5" value="0.01" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Improvement From Baseline in Serum C-Reactive Protein (CRP) At Week 2 (Part A and Part B)</title>
        <description>Serum CRP is a marker of systemic inflammation. A negative change from baseline in CRP represents improvement.</description>
        <time_frame>Baseline, Week 2</time_frame>
        <population>Population analyzed included randomized participants in Part A (excluding a site based on sponsor audit for data integrity) and Part B. Here 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received placebo subcutaneously (SC) at Week 0 and every 2 weeks (q2w) for 10 weeks. Thereafter participants received sirukumab 100 milligram (mg) beginning at Week 12 and q2w through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Sirukumab 100 mg q2 Weeks</title>
            <description>Participants received 100 mg of sirukumab subcutaneously at Weeks 0, 2 and every 2 weeks (q2w) through Week 24.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Sirukumab 100 mg q4 Weeks</title>
            <description>Participants received 100 mg of sirukumab subcutaneously at Week 0 and every 4 weeks (q4w) for 24 weeks and placebo SC injections at Weeks 2, 6, and q4w through week 22.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Sirukumab 50 mg q4 Weeks</title>
            <description>Participants received 50 mg of sirukumab subcutaneously at Week 0 and every 4 weeks (q4w) for 24 weeks and placebo SC injections at Weeks 2, 6, and q4w through week 22.</description>
          </group>
          <group group_id="O5">
            <title>Part B: Sirukumab 25 mg q4 Weeks</title>
            <description>Participants received 25 mg of sirukumabat subcutaneously at Week 0 and every 4 weeks (q4w) for 24 weeks and placebo SC injections at Weeks 2, 6, and q4w through week 22.</description>
          </group>
          <group group_id="O6">
            <title>Part A: Placebo</title>
            <description>Participants received placebo subcutaneously (SC) at Week 0 and every 2 weeks (q2w) for 10 weeks. Thereafter participants received sirukumab 100 mg beginning at Weeks 12 and q2w through week 22.</description>
          </group>
          <group group_id="O7">
            <title>Part A: Sirukumab 100 mg q2 Weeks</title>
            <description>Participants received 100 mg of sirukumab subcutaneously at Weeks 0, 2 and every 2 weeks (q2w) for Week 10. Thereafter participants received placebo beginning at Weeks 12 and q2w through week 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Improvement From Baseline in Serum C-Reactive Protein (CRP) At Week 2 (Part A and Part B)</title>
          <description>Serum CRP is a marker of systemic inflammation. A negative change from baseline in CRP represents improvement.</description>
          <population>Population analyzed included randomized participants in Part A (excluding a site based on sponsor audit for data integrity) and Part B. Here 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="17"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.31" spread="246.040"/>
                    <measurement group_id="O2" value="81.46" spread="25.000"/>
                    <measurement group_id="O3" value="88.53" spread="12.675"/>
                    <measurement group_id="O4" value="85.42" spread="18.242"/>
                    <measurement group_id="O5" value="81.22" spread="24.484"/>
                    <measurement group_id="O6" value="19.97" spread="41.232"/>
                    <measurement group_id="O7" value="91.19" spread="4.812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Screening up to Week 38</time_frame>
      <desc>Safety population (SP) included all participants who received at least 1 dose of study agent (including safety data from all investigator sites irrespective of audit findings).</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A - Placebo (Wk 0-Wk 12)</title>
          <description>Participants received placebo subcutaneously (SC) at Week 0 and every 2 weeks (q2w) for 10 weeks</description>
        </group>
        <group group_id="E2">
          <title>Part A - Placebo Then Sirukumab (Wk 12 to End of Study)</title>
          <description>Participants received 100 mg of sirukumab subcutaneously at Weeks 0, 2 and every 2 weeks (q2w) for Week 10. Thereafter participants received placebo beginning at Weeks 12 and q2w through week 22.</description>
        </group>
        <group group_id="E3">
          <title>Part A - Sirukumab (Wk 0-Wk 12)</title>
          <description>Participants received 100 mg of sirukumab subcutaneously at Weeks 0, 2 and every 2 weeks (q2w) for Week 10.</description>
        </group>
        <group group_id="E4">
          <title>Part A - Sirukumab Then Placebo (Wk 12 to End of Study)</title>
          <description>Participants received placebo at Weeks 12 and q2w through Week 22.</description>
        </group>
        <group group_id="E5">
          <title>Part B - Placebo (Wk 0-Wk 12)</title>
          <description>Participants received placebo subcutaneously (SC) at Week 0 and q2w for 10 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Part B - Placebo Then Sirukumab 100 mg q2 Weeks</title>
          <description>Participants received placebo subcutaneously (SC) at Week 0 and every 2 weeks (q2w) for 10 weeks. Thereafter participants received sirukumab 100 mg beginning at Weeks 12 and q2w through week 24.</description>
        </group>
        <group group_id="E7">
          <title>Part B - Sirukumab 100mg q2w</title>
          <description>Participants received 100 mg of sirukumab subcutaneously at Weeks 0, 2 and every 2 weeks (q2w) through Week 24.</description>
        </group>
        <group group_id="E8">
          <title>Part B - Sirukumab 100mg q4w</title>
          <description>Participants received 100 mg of sirukumab subcutaneously every 4 weeks (q4w) for 24 weeks and in between placebo SC injections was received at Weeks 2, 6, and q4w through week 22.</description>
        </group>
        <group group_id="E9">
          <title>Part B - Sirukumab 50mg q4w</title>
          <description>Participants received 50 mg of sirukumab subcutaneously every 4 weeks (q4w) for 24 weeks and in between placebo SC injections was received at Weeks 2, 6, and q4w through week 22.</description>
        </group>
        <group group_id="E10">
          <title>Part B - Sirukumab 25mg q4w</title>
          <description>Participants received 25 mg of sirukumab subcutaneously every 4 weeks (q4w) for 24 weeks and in between placebo SC injections was received at Weeks 2, 6, and q4w through week 22.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA: 13.0,13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bursitis Infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cellulitis Staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pelvic Inflammatory Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Fibrosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Facial Paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Intracranial Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vertebral Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA: 13.0,13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="25" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="23" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic Diathesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bundle Branch Block Left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Aphthous Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection Site Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection Site Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection Site Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection Site Warmth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Staphylococcal Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Synovial Rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood Cholesterol Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood Insulin Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood Potassium Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Insulin Resistance Test</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Intraocular Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tendon Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director</name_or_title>
      <organization>Janssen Research &amp; Development, LLC</organization>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

